Thinking Outside the Box… and Inside the Container: FDA’s Draft Guidance for Contained Expectations
Welcome back! Today we’re talking about packaging for human drugs and biological products, a part of product quality. On 08/13/2026, the Food and Drug Administration (FDA) released the draft guidance, “Container Closure Systems for Human Drugs and Biological Products”. The message is simple; FDA expects companies to understand how a container closure system (CCS) protects the product throughout its life. That means the container, closure, seal, liner, label-facing surface, and any product contact materials may need to be evaluated not only as separate parts, but as a complete system that can affect quality, safety, strength, purity, identity, performance, and doing all of this while using a risk-based approach. Let’s dive in!
Tissue-based products and biologically derived materials can be especially sensitive to their environment. Temperature changes, moisture, light, sterilization residues, extractables, leachables, particulates, seal integrity, handling conditions (just to name a few) all impact the product. A component that looks acceptable on paper may still create risk if it interacts with the product, fails during storage, or cannot withstand the real shipping and use conditions.
What should manufacturers expect? Here are some considerations:
Expect more questions about risk. FDA reviewers may look for a clear explanation of why a container closure system is appropriate for the product it holds. Higher-risk products, novel materials, new technologies, or products with direct contact between the container and biologic may call for more supporting data.
Expect closer attention to compatibility. Manufacturers may need to show that the system does not negatively affect the product and that the product does not damage the system. This can include chemical, physical, microbiological, and functional compatibility over the intended shelf life.
Expect lifecycle thinking. FDA’s approach is not limited to what happens on the day a container is filled. Companies should think through procurement, incoming inspection, sterilization, filling, sealing, storage, transport, thawing, preparation for use, and any real-world handling that could impact performance.
Expect stronger documentation. Even when a company already has sound practices, the draft guidance signals the need to connect the dots in writing. FDA may expect a well-organized rationale supported by specifications, supplier information, test methods, validation records, change controls, complaints, deviations, and stability data.
How should manufacturers prepare?
Consider your container closure system. List all product contact and critical non-product contact components where they help protect product quality.
Rank risk by product and use. Consider how sensitive the product is, how long it is stored (e.g., whether it is frozen, refrigerated, lyophilized, hydrated, terminally sterilized, aseptically processed, etc.) including how it is exposed to repeated handling.
Review supplier files. Confirm material identity, specifications, certificates, change notification commitments, sterilization records, biocompatibility information, extractable or leachable data, and manufacturing controls.
Check gaps in testing by looking at container closure integrity, microbial barrier performance, particulates, moisture protection, light or oxygen protection, seal strength, shipping qualification, freeze-thaw performance, and compatibility with intended manufacturing conditions.
Update change control triggers by ensuring your procedures catch supplier changes (e.g., resin changes, sterilization changes, mold changes, adhesive changes, packaging configuration changes etc.) before they reach production.
Bottom line, for manufacturers, FDA’s draft guidance is a reminder that the package is not just a package. It is part of the product’s protection system. The focus is on ensuring safety, performance, and compatibility throughout the product lifecycle. The companies that will be best prepared are the ones that can explain in plain terms and with solid evidence, why their container closure systems are suitable for the products they protect over the intended shelf life. Now is the time to get organized, review your systems, tighten supplier controls, document your rationale, and make sure your evidence tells a complete story. Preparation today can reduce challenges tomorrow!
Thanks for joining! Keep checking back as we continue bringing you industry trending topics!
Have questions? Contact us here!
Reference: